RankAlpha logo

ADMA

AI Memo

ADMA Biologics

As of 2026-10-25/Confidence medium/Horizon 6‑12m
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
medium
Horizon
6‑12m
Key catalyst
ASCENIV real-world evidence at ACAAI • 2026-11-30
Base target: $12 / p=1% prob
Biggest risk
Total second-quarter revenue grew only 2% despite ASCENIV's 24% growth. Competitive pricing pressure on BIVIGAM could continue to offset ASCENIV gains, while the real-world evidence may not translate into faster sales. [#SEC-8K-2026-08-05]
Invalidation
Break below $8 or thesis failure.
What would change my mind?
ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition. ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges. [#SEC-8K-2026-08-05]
Research note
Recommendation
—
Confidence
medium
As of
2026-10-25
Base target
$12
p=1%
Bull target
$15
p=0%
Bear target
$8
p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition.
  • ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges.
  • [#SEC-8K-2026-08-05]
BearKey bullets
  • Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization.
  • [#SEC-8K-2026-08-05]
  • Persistent competition and pricing pressure in the standard U.S.
WatchKey bullets
  • ASCENIV real-world evidence at ACAAI

Summary

High-level snapshot

Recommendation
-
Model confidence
medium
Timeframe
6‑12m
Asset
Equity
Trigger
-
Base case: $12 (p=1%)
Target spread vs base: +25% / -37%
Scenario probabilities
Bull Target: $15 (p=0%)Base Target: $12 (p=1%)Bear Target: $8 (p=0%)
Commentary
Company-reported ASCENIV growth and reiterated guidance are constructive, but the outlook was not raised. A September 4 Zacks recap reported shares down about 4.8% in the month after earnings; this is not an immediate post-release reaction. Current analyst revisions, options skew, short interest, employee ratings and social sentiment were not verified. Zero-valued sentiment fields denote unavailable data, not neutral readings.
As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition. ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges. [#SEC-8K-2026-08-05]
Bear Case
Total second-quarter revenue grew only 2% despite ASCENIV's 24% growth. Competitive pricing pressure on BIVIGAM could continue to offset ASCENIV gains, while the real-world evidence may not translate into faster sales. [#SEC-8K-2026-08-05]

Drivers

Scannable catalysts and supporting factors

  • ASCENIV adoption and favorable product mix sustain growth and profitability despite standard immune-globulin competition.
  • ADMA reiterated its 2026 revenue, adjusted-net-income and adjusted-EBITDA ranges.
  • [#SEC-8K-2026-08-05]

Scenarios

Bull Target (Scenario probability)
$15 / p=0% prob
Base Target (Scenario probability)
$12 / p=1% prob
Bear Target (Scenario probability)
$8 / p=0% prob
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-11-30
    ASCENIV real-world evidence at ACAAI
    ADMA submitted an abstract covering 127 ASCENIV-treated patients for the November 2026 ACAAI meeting. Disclosure could strengthen the product's commercial evidence base, but incremental sales remain unproven. November 30 is a monitoring date, not a confirmed presentation date. [#SEC-8K-2026-08-05]
    Prob 65.00% • Move 5.00% • Priced-in 25.00%
  • EVENT2026-12-31
    ASCENIV growth against reiterated 2026 guidance
    Second-quarter ASCENIV revenue rose 24% year over year to $102.9 million, while total revenue rose 2% to $124.4 million. ADMA reiterated 2026 revenue guidance of $530 million–$560 million. The test is whether ASCENIV uptake continues to offset pressure in the standard immune-globulin market; December 31 is a fiscal-year monitoring date, not an announced results date. [#SEC-8K-2026-08-05] [#8-K-2026-08-05]
    Prob 65.00% • Move 8.00% • Priced-in 45.00%

Risks

  • Heavy reliance on ASCENIV growth leaves results sensitive to any slowdown in adoption or utilization. [#SEC-8K-2026-08-05]
  • Persistent competition and pricing pressure in the standard U.S. immune-globulin market are explicitly reflected in ADMA's 2026 outlook. [#SEC-8K-2026-08-05]
  • Submitted real-world evidence is not proof of incremental commercial uptake or a regulatory milestone. [#SEC-8K-2026-08-05]

Peers

SymbolSummary
CSLCSL provides an immunoglobulin demand and manufacturing reference, but its greater scale and diversification make it an imperfect valuation peer.
GRFSGrifols is a closer plasma-derived immunoglobulin operating reference than the packet's market-cap matches, though its broader business limits valuation comparability.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-10-25